PT-141 Dosage - Bremelanotide Dosing, Timing and Half-Life
PT-141 (bremelanotide) is a melanocortin receptor agonist with a single FDA-approved dosage: 1.75 mg injected subcutaneously at least 45 minutes of lead time ahead of the event, never more than once in 24 hours and no more than 8 times a month. This article deals with the practical side of that schedule rather than the general pharmacology. It explains how the approved pt-141 dosage is defined, how the 45-minute window and the 24-hour rule work, what a terminal half-life of about 2.7 hours means for repeat injections, which side effects are dose-related, who should not use the drug, and how a lyophilised research vial is reconstituted and stored. Everything below is educational reference material, not medical advice, and the vial form sold for laboratory work is not for human consumption.
Related searches: pt-141 dosage, pt-141 dosing, bremelanotide dose, pt-141 half life, pt-141 side effects, bremelanotide injection, how much pt-141 to take.
PT-141 Dosage - The Approved Number and the Doses Studied
The approved bremelanotide dose is fixed. Vyleesi is supplied as a single-dose autoinjector containing 1.75 mg of bremelanotide in 0.3 mL of clear solution, and the label instructs the patient to inject that full dose under the skin of the abdomen or thigh. There is no titration schedule and no oral form: the product is a prefilled pen and the dose is not adjusted by body weight. The same label limits the indication to premenopausal women with acquired, generalized hypoactive sexual desire disorder, and states that the medicine is not indicated for postmenopausal women or for men, and is not intended simply to enhance sexual performance.
The 1.75 mg figure did not come from a single trial. A phase 2b dose-ranging study in premenopausal women compared subcutaneous doses of 1.25 mg and 1.75 mg, and both produced measurable improvement over placebo on desire and arousal measures. The higher 1.75 mg dose was carried into the two phase 3 trials that supported approval, and it is the only strength that exists in the marketed autoinjector. Anyone reading online posts about a bremelanotide dose below or above this level should treat those numbers as research or off-label references rather than approved dosing.
For context, PT-141 is a derivative and metabolite of the older tanning peptide Melanotan II. The two are frequently confused, but their dosing patterns are quite different: Melanotan II was researched with repeated loading injections, while PT-141 was designed for single, on-demand use.
| Parameter | PT-141 (bremelanotide) reference |
|---|---|
| Approved single dose | 1.75 mg subcutaneously |
| Concentration in the autoinjector | 1.75 mg per 0.3 mL |
| Injection site | Abdomen or thigh |
| Timing | At least 45 minutes of lead time ahead of the event |
| Minimum spacing | No more than 1 dose in any 24 hours |
| Monthly limit | More than 8 doses per month is not recommended |
| Stop rule | Discontinue after 8 weeks if symptoms have not improved |
PT-141 Dosing and Timing - The 45-Minute Window and the 24-Hour Rule
Timing is the part of pt-141 dosing that generates the most questions. The label tells patients to inject at least 45 minutes of lead time ahead of the event, and then adds a caveat that the duration of efficacy after each dose is unknown and that the optimal administration window has not been fully characterised. In other words, 45 minutes is a floor, not a precise target. The pharmacokinetic data support that floor: after a subcutaneous injection the median time to peak plasma concentration is about 1.0 hour, with a reported range of 0.5 to 1.0 hours, so peak blood levels generally coincide with the first hour after the injection.
Because the effect is judged subjectively by the person using it, the label allows patients to choose the timing that works for them once they understand how they respond and how long any nausea lasts. What the label does not allow is stacking doses. More than one dose within 24 hours is prohibited, because the efficacy of consecutive doses has not been established and because doses given close together may add to the blood pressure effect. The monthly ceiling exists for a related reason: few patients in the phase 3 programme received more than 8 doses per month, and more frequent dosing increases both the risk of focal hyperpigmentation and the total time each month during which blood pressure is raised. In the trials most participants used the injection two to three times a month and never more than once a week, even though the study protocol permitted up to twelve doses per month.
| Time after injection | What the label reports |
|---|---|
| 0 minutes | Subcutaneous dose given in the abdomen or thigh, at least 45 minutes before activity |
| 0.5 to 1 hour | Median peak plasma concentration, at about 1 hour |
| Within 1 hour | Median onset of nausea, which lasts about 2 hours |
| 2 to 4 hours | Peak rise in blood pressure, about 6 mmHg systolic and 3 mmHg diastolic |
| Up to 12 hours | Blood pressure and heart rate usually return to baseline |
| 24 hours | Earliest time a further dose may be given |
PT-141 Half Life - What About 2.7 Hours Means for Repeat Dosing
Bremelanotide clears from plasma with a terminal half-life reported as roughly 2.7 hours (range 1.9 to 4.0 hours) and a mean clearance of 6.5 L per hour. The volume of distribution is about 25 L and only 21 percent of the drug binds to human serum protein, so the compound leaves plasma relatively quickly. Bremelanotide is a seven-amino-acid cyclic peptide, and its primary metabolic route is hydrolysis of the amide bonds of that ring rather than liver enzyme pathways. In a radiolabelled study, 64.8 percent of the dose was recovered in urine and 22.8 percent in faeces.
A short plasma half-life explains why the injection is on-demand rather than daily, but it does not fully describe the effect. The label explicitly notes that the duration of efficacy is unknown, and the time to peak receptor effect does not have to match the plasma curve. For practical purposes two facts follow from the numbers. First, the drug is essentially cleared within a day, so if a person wants two separate doses they must be spaced at least 24 hours apart. Second, because there is no accumulation from dose to dose in that pattern, the label reports no additive blood pressure or heart rate effect when the injection is repeated daily, 24 hours apart, for up to 16 days.
Kidney and liver function do change exposure. In patients with mild, moderate and severe renal impairment the total exposure to bremelanotide rose about 1.2-fold, 1.5-fold and 2-fold respectively. Mild and moderate hepatic impairment raised exposure about 1.2-fold and 1.7-fold. The label does not specify an adjusted strength for these groups, so anyone with reduced kidney or liver function has a further reason to have both the decision and the monitoring handled by a clinician.
PT-141 Side Effects - Nausea, Blood Pressure and Hyperpigmentation
The side effect profile is the strongest argument for keeping the dose at the approved level. In the pooled phase 3 trials the most common reactions were nausea, flushing, injection site reactions, headache and vomiting. Most events were mild or moderate and transient, but the discontinuation rate due to adverse reactions was 18 percent on bremelanotide compared with 2 percent on placebo.
- Nausea - reported by 40 percent of treated patients versus 1 percent on placebo, and severe enough to require anti-emetic medication in 13 percent. It began within about one hour of the injection and lasted about two hours. Nausea was most frequent after the first dose, reported in 21 percent of patients, and fell to roughly 3 percent with later doses
- Flushing - reported in about 20 percent of treated patients, usually mild and rarely severe
- Headache - reported in about 11 percent of treated patients versus about 2 percent on placebo
- Injection site reactions - reported in about 13 percent, including pain, redness, bruising, bleeding, itching and altered sensation
- Vomiting - reported in about 5 percent of treated patients
- Transient blood pressure rise - a maximal increase of about 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose and returning to baseline usually within 12 hours
- Heart rate reduction - a fall of up to 5 beats per minute alongside the blood pressure change
- Focal hyperpigmentation - dark patches including the face, gums and breasts, reported in 1 percent of patients taking up to 8 doses per month. In a separate study, 38 percent developed pigmentation after daily dosing for 8 days, and a further 14 percent after 8 more daily doses. Darker skin was a risk factor, and resolution was not confirmed in all patients after stopping
Two practical points stand out. Pre-treatment with oral ondansetron 30 minutes before the injection did not reduce the incidence of nausea in a phase 4 study and is not recommended as a preventive measure. And because a single case of acute hepatitis was reported during an open-label extension phase, the label lists liver-related monitoring among the reasons to involve a physician rather than self-manage the drug.
Who Should Not Use It - Contraindications, Food and Unapproved Routes
Bremelanotide is contraindicated in people with uncontrolled hypertension or known cardiovascular disease, and it is not recommended for those at high risk of cardiovascular disease, precisely because it raises blood pressure with every dose. The effect is transient, but it repeats each time the drug is taken. Because the product is for premenopausal women, patients are advised to use effective contraception and to stop the medicine if pregnancy is suspected. The approved route is subcutaneous injection only.
Food is a common source of confusion here. The label does not describe a food effect on the absorption of a subcutaneous injection, and the absolute bioavailability by that route is about 100 percent, with no significant difference between the abdomen and the thigh as injection sites. Where the drug does interact is with other medicines taken by mouth: bremelanotide can slow gastric emptying and change the absorption of oral drugs, and it significantly reduces the systemic exposure of orally administered naltrexone, so that combination is to be avoided. Alcohol has been studied separately, and a phase 1 trial found that bremelanotide and ethanol could be coadministered and were generally well tolerated.
Other routes have been tried and shelved. PT-141 was originally developed as an intranasal product, but wider variation in plasma levels and increases in blood pressure in some users led the developer to discontinue the nasal formulation as a first-line therapy. Subcutaneous delivery reduced that variability and became the approved route. There is no approved oral, sublingual or inhaled form, so any such use should be regarded as unapproved and unsupervised.
Reconstituting and Storing a PT-141 Research Vial
Research suppliers, including Dragon Pharma, sell PT-141 as a lyophilised powder rather than a ready pen. A 10 mg vial of the peptide plus 2 mL of bacteriostatic water with 0.9 percent benzyl alcohol brings the vial to 5 mg/mL, which is the calculation behind most laboratory dilution charts. The handling sequence is straightforward. Bring the vial to room temperature before opening it, direct the diluent along the glass rather than at the powder, and swirl gently: foaming and denaturation come from shaking, then label the vial with the date and the final concentration.
Storage follows the standard peptide rules. Supplier guidance for the reconstituted solution calls for refrigeration at 2 to 8 degrees Celsius and use within about 28 days, which matches the multi-dose window that a 0.9 percent benzyl alcohol preservative is designed to allow. Lyophilised powder that will be kept for months is better stored dry and cold, below minus 15 degrees Celsius according to published peptide handling guidance, with short-term storage in an ordinary refrigerator acceptable. Repeated freezing and thawing of a solution is best avoided. None of this is a human dosing instruction: research peptides are sold for laboratory investigation and are not for human consumption.